Research lines
Our research starts from a simple but not yet exploited truth: aging and prior cancer therapy are the strongest predictors of cancer. Both act as ecological stressors that reshape the tissue environment, draining key metabolic resources and altering the fitness landscape of cells. We think this shift is key to understanding why normal and immune cells lose their competitive edge, while precancerous clones adapt and thrive. By uncovering and reprogramming these metabolic bottlenecks, we aim to restore balance—preventing cancer, improving immunotherapy, and protecting survivors.
Tumorigenesis in the Metabolically Aged TME
​
We investigate how metabolic scarcities rewire tissue ecology in the colon and in the bone marrow, giving precancerous clones a competitive advantage. Our goal: strategies to delay or prevent cancer initiation and relapse.
Metabolic Aging of Anti-Tumor Immunity
​
Immune cells depend on metabolic resources to function. We study how aging and therapy restrict these resources, driving immune failure — and how restoring supply chains could break resistance to immunotherapy.
Metabolism of Cancer Survivorship and Recurrence
​
Survivors carry the long-term metabolic scars of therapy. We ask how prior treatment reshapes tissue ecology, accelerates aging, and increases cancer and relapse risk — and how interventions can restore healthier tissue metabolism for prevention of late effects and relapse.